Mark Fineman

Mark Fineman, PhD

Chief Scientific Officer

Mark Fineman joined Elcelyx in 2011 and currently serves as our Chief Scientific Officer. Prior to joining the company, he spent over 20 years at Amylin Pharmaceuticals where he was instrumental in growing the company from a small early development organization to a fully-integrated commercial operation. During his tenure at Amylin, Dr. Fineman held several leadership positions in Medical Development, Clinical Pharmacology/Translational Medicine and Medical Affairs. Dr. Fineman was the Development Core Team leader for Byetta® (exenatide for treatment of type 2 diabetes) through US and European market authorization. He was also responsible for Clinical and Regulatory Affairs at Psylin Neurosciences, Inc., a virtual biotech company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics Inc. to evaluate peptide hormones for the treatment of psychiatric disorders. Dr. Fineman has authored over 40 original publications and is an inventor on several patents.

Dr. Fineman graduated from California Polytechnic State University, San Luis Obispo with a B.S. in Microbiology (Clinical Chemistry emphasis) and received Master’s of Science and Master’s of Advanced Studies degrees in Molecular Pathology and Clinical Research from the University of California, San Diego. Dr. Fineman received a PhD in medicine at Vrije Universiteit Amsterdam.